NYSE · ARCH
Energy · Coal
$134.83
Up+$0.94 (+0.70%)
Updated Sep 10, 2026, 9:37 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
ARCH does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning ARCH.
ARCH research
Company profile and research snapshot.
Arch Resources, Inc. produces and sells thermal and metallurgical coal from surface and underground mines. As of December 31, 2021, the company operated seven active mines. It also owned or controlled primarily through long-term leases approximately 28,292 acres of coal land in Ohio; 952 acres of coal land in Maryland; 10,095 acres of coal land in Virginia; 306,033 acres of coal land in West Virginia; 81,470 acres of coal land in Wyoming; 234,543 acres of coal land in Illinois; 33,047 acres of coal land in Kentucky; 362 acres of coal land in Montana; 248 acres of coal land in Pennsylvania; and 19,018 acres of coal land in Colorado, as well as smaller parcels of property in Alabama, Indiana, Washington, Arkansas, California, Utah, and Texas. The company sells its products to utility, industrial, and steel producers in the United States, Europe, Asia, Central and South America, and Africa. The company was formerly known as Arch Coal, Inc. and changed its name to Arch Resources, Inc. in May 2020. Arch Resources, Inc. was incorporated in 1969 and is headquartered in St. Louis, Missouri.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jan 6, 2025 | Jefferies | Buy | — |
| Nov 18, 2024 | Benchmark | Buy | — |
| Nov 13, 2024 | Jefferies | Hold | — |
| Sep 6, 2024 | B. Riley Securities | Buy | — |
| Jul 29, 2024 | B. Riley Securities | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Dec 14, 2024
Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties to shareholders related to the proposed sales of Zuora, Inc., Arch Resources, Inc., and the merger of Cyclo Therapeutics, Inc. with Rafael Holdings, Inc.
GlobeNewswire Inc. · Jun 27, 2024
TORONTO, June 27, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced that Dalton Pharma Services (Dalton) has completed the good manufacturing practice (GMP) glass vial filling stage for cilastatin, the Company’s second drug candidate for preventing acute kidney injury (AKI).
GlobeNewswire Inc. · Jun 18, 2024
TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University of Calgary’s Conjoint Health Research Ethics Board (CHREB) has approved the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
Zacks Investment Research · Apr 18, 2024
Arch Resources (ARCH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ARCH.
No results
No recent SID articles mention ARCH.
